DOCSLIB.ORG

The Journal Receives Funding from the Ministry of Science and Higher Education for Promoting Scientific Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Journal Receives Funding from the Ministry of Science and Higher Education for Promoting Scientific Research EDITORIAL STAFF EDITORIAL BOARD Rafał Krenke, MD, PhD Warsaw, Poland EXECUTIVE EDITOR Franciszek Kokot, MD, PhD Eugeniusz J. Kucharz, MD, PhD Grzegorz Gajos, MD, PhD Katowice, Poland (Co-Chair) Katowice, Poland Roman Jaeschke, MD, MSc STATISTICAL CONSULTANT Jan Kulpa, MD, PhD Hamilton, ON, Canada (Co-Chair) Agnieszka Pac, PhD Kraków, Poland Małgorzata Bała, MD, PhD Jolanta Małyszko, MD, PhD MANAGING EDITOR Kraków, Poland Białystok, Poland Maria Piasecka, PhD MD, PhD Tomasz Brzozowski, Jacek Musiał, MD, PhD MANUSCRIPT EDITING Kraków, Poland Kraków, Poland Małgorzata Kurowska Flavio Coceani, MD Paul O'Byrne, MD, PhD Małgorzata Wiesner-Spyrczyńska Pisa, Italy Hamilton, ON, Canada Deborah Cook, MD, PhD SOCIAL MEDIA EDITOR Grzegorz Opolski, MD, PhD Hamilton, ON, Canada Zbigniew Heleniak, MD, PhD Warsaw, Poland Mark Crowther, MD, MSc, FRCPC Ralf Paschke, MD, PhD DTP Hamilton, ON, Canada Calgary, Canada Tomasz Śmigla Stanisław Czekalski, MD, PhD Marek Sanak, MD, PhD ADDRESS Poznań, Poland Kraków, Poland Cholerzyn 445 Anna Członkowska, MD, PhD Holger Schünemann, MD, PhD 32-060 Liszki, Poland Warsaw, Poland Hamilton, ON, Canada phone: +48 12 293 42 20 fax: +48 12 293 40 10 James Douketis, MD, FRCPC Tomasz Stompór, MD, PhD email: [email protected] Hamilton, ON, Canada Olsztyn, Poland www.mp.pl/paim Józef Drzewoski, MD, PhD Krzysztof Strojek, MD, PhD Łódź, Poland Copyright by Medycyna Praktyczna, Katowice, Poland Kraków 2019 Artur Dziewierz, MD, PhD Michał Tendera, MD, PhD Kraków, Poland Katowice, Poland PUBLISHER Piotr Głuszko, MD, PhD Medycyna Praktyczna Anetta Undas, MD, PhD Warsaw, Poland Kraków, Poland INDEXED IN Gordon Guyatt, MD, PhD Jadwiga Wedzicha, MD, PhD Chemical Abstracts Service (CAS), Hamilton, ON, Canada London, UK Crossref, Database of Abstracts of Andrzej Januszewicz, MD, PhD Reviews of Effects (DARE), EBSCO, Albert W. Wu, MD, PhD Warsaw, Poland EMBASE, GENAMICS, Geneva Baltimore, USA Foundation Free Medical Journals, Barbara Jarząb, MD, PhD Krystyna Zawilska, MD, PhD Index Copernicus (IC), J-Gate, Master Gliwice, Poland Poznań, Poland Journal List, MNiSW, National Library Wiesław W. Jędrzejczak, MD, PhD Irena Zimmermann-Górska, MD, PhD of Medicine (NLM), Polish Medical Warsaw, Poland Poznań, Poland Library (GBL), PubMed/MEDLINE, Irina Kowalska, MD, PhD Science Citation Index Expanded (SCI-Ex), Dorota Zozulińska-Ziółkiewicz, MD, PhD Białystok, Poland SciFinder, Scopus, TUMS Digital Library, Poznań, Poland Web of Science Core Collection Print ISSN: 0032-3772 Online ISSN: 1897-9483 Impact Factor 2018 = 2.882 OPEN ACCESS This is an Open Access publication distributed under the terms of the Creative Commons The journal receives funding from Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties the Ministry of Science and Higher Education to copy and redistribute the material in any medium or format and to remix, transform, and build upon for promoting scientific research the material, provided the original work is properly cited, distributed under the same license, and used for (agreement no. 595/P-DUN/2019). noncommercial purposes only. For commercial use, please contact the journal office at [email protected]. Jak zamawiać publikacje MP SPOSOBY SKŁADANIA ZAMÓWIEŃ • telefonicznie (pn.–pt., 8.00–18.00) pod numerami: 800 888 000 (z telefonów stacjonarnych, bezpłatna infolinia) 12 293 40 80 (z telefonów komórkowych i stacjonarnych) • na stronie internetowej ksiegarnia.mp.pl • e‑mailem pod adresem [email protected] (w treści zamówienia prosimy podać tytuły zamawianych pozycji lub ich numery katalogowe, adres korespondencyjny, dane do wystawienia faktury, wybrany sposób płatności) • przesyłając do Wydawnictwa wypełniony formularz zgody na obciążenie rachunku (polecenia zapłaty) dostępny na stronie internetowej ksiegarnia.mp.pl FORMY PŁATNOŚCI • przelew bankowy / przekaz pocztowy: Medycyna Praktyczna, Cholerzyn 445, 32‑600 Liszki numer konta: 35 1600 1039 0002 0033 3552 6001 • karta kredytowa • przy odbiorze przesyłki (zaliczenie pocztowe) • polecenie zapłaty (formularz zgody na obciążenie rachunku dostępny na stronie ksiegarnia.mp.pl) KOSZTY PRZESYŁEK • Koszt przesyłki zamówionych książek oraz jednorazowy koszt zamówienia prenumeraty wynosi 12 zł. Powyższe ceny obowiązują wyłącznie na terenie Polski. INFORMACJE DODATKOWE Prenumeratorzy czasopism Wydawnictwa mają prawo do zniżki przy zakupie jednego egzemplarza każdej książki i wydania specjalnego. Na naklejce adresowej znajdują się informacje dotyczące: • zawartości przesyłki • kwoty informującej o ewentualnej nadpłacie lub niedopłacie w stosunku do zamówienia • ostatniego opłaconego lub zamówionego numeru każdego z czasopism KONTAKT • telefoniczny (pn.–pt., 8.00–18.00) pod numerami: 800 888 000 (z telefonów stacjonarnych, bezpłatna infolinia) 12 293 40 80 (z telefonów komórkowych i stacjonarnych) • pocztą elektroniczną ([email protected]) An official journal of the Polish Society of Internal Medicine founded by professor Władysław Antoni Gluziński MONTHLY VOL. 129 (SPECIAL IssUE 3) 2019 ABSTRACT PART I GENERAL OVERVIEW OF MAJOR VIRAL INFECTIONS 7 Cytomegalovirus 10 BK virus 14 Epstein–Barr virus 15 Influenza 16 Hepatitis C virus 17 HIV 21 Human papilloma virus PART II SPECIFIC ISSUES IN MANAGEMENT OF VIRAL INFECTIONS IN TRANSPLANT RECIPIENTS 23 Viruses versus myocarditis and acute coronary syndromes 24 Viruses and kidney transplant eligibility 25 Treatment of hepatitis B virus infection in transplant recipients 27 Viral infections in kidney and upper extremity transplant recipients 28 Histological diagnosis of BK virus and cytomegalovirus infections 29 Viral diarrhea 29 Ground glass opacification PART III COMMENTARY 35 The art of immunosuppression in liver transplantation: personal reflections based on a 40-year career ABSTRACT The 3 leading causes of death in patients after sol‑ Immunosuppressive treatment impairs the im‑ id organ transplantation (SOT) include cardiovas‑ mune function, which renders the patient more cular diseases, malignancies, and infections. Ac‑ susceptible to infections. Furthermore, treat‑ cording to our current understanding, the latter ment of infections in immunocompromised pa‑ play the key role in the pathogenesis of athero‑ tients poses a challenge and SOT. sclerosis. Similarly, infections (mainly viral) are The current publication provides a brief summa‑ implicated in the pathogenesis of at least 20% of ry of the key information provided in 20 lectures known neoplasms. In other words, the implica‑ on viral infections in patients after SOT delivered tions of acute and chronic infectious diseases in during the 9th Practical Transplantology Course in modern medicine, not only transplantology, are Warsaw, Poland on September 15–16, 2017. significant and ever ‑increasing. PART I General overview of major viral infections Krzysztof Mucha1,2*, Bartosz Foroncewicz1*, Alicja Dębska ‑Ślizień3, Magdalena Durlik4, Ryszard Grenda5, Andrzej Horban6, Piotr Fiedor7, Magdalena Krajewska8, Artur Kwiatkowski7, Jan Lerut1,9, Jacek Małyszko10, Jolanta Małyszko11,12, Piotr Przybyłowski13,14, Krzysztof Zieniewicz15, Michał Ciszek1, Dorota Kamińska9, Maciej Kosieradzki8, Agnieszka Perkowska ‑Ptasińska5, Justyna Czerniawska16, Dominika Dęborska5, Radosław Kwieciński14, Magdalena Kwapisz8, Barbara Moszczuk1, Leszek Pączek1,2 1 Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland 2 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland 3 Department of Nephrology, Transplantology and Internal Medicine, Gdańsk Medical University, Poland 4 Department of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, Poland 5 Department of Nephrology, Kidney Transplantation and Hypertension, The Children’s Memorial Health Institute, Warsaw, Poland 6 Department for Adult’s Infectious Diseases, Medical University of Warsaw, Poland 7 Department of General and Transplantation Surgery, Medical University of Warsaw, Poland 8 Chair and Department of Nephrology and Transplantation Medicine, Wrocław Medical University, Wrocław, Poland 9 Starzl Unit Abdominal Transplantation, University Hospitals Saint Luc, Université Catholique de Louvain, Brussels, Belgium 10 1st Department of Nephrology and Transplantology with Dialysis Unit, Medical University of Białystok, Białystok, Poland 11 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Białystok, Poland 12 Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland 13 1st Chair of General Surgery, Jagiellonian University, Medical College, Kraków, Poland 14 Silesian Center for Heart Diseases, Zabrze, Poland 15 Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland 16 Department of Radiology, Medical University of Warsaw, Poland Cytomegalovirus infection Immune response to cy- termed “a 40­­‑day fever”, due to an increase of tomegalovirus in solid organ transplant recipient Cy‑ body temperature with the onset on day 40 fol‑ tomegalovirus (CMV) is one of the most common lowing transplantation, present in most cases. opportunistic pathogens in individuals with pri‑ Depending on the transplanted organ, CMV in‑ mary or secondary immunodeficiency, such as fection may present as: a) bronchiolitis obliter‑ organ transplant recipients. Prior to the intro‑ ans syndrome or interstitial pneumonia, some‑ duction of ganciclovir (GCV), which is common‑ times leading to respiratory
Load more

Recommended publications
  • SAMHD1 . . . and Viral Ways Around It
    viruses Review SAMHD1 . and Viral Ways around It Janina Deutschmann and Thomas Gramberg * Institute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany; [email protected] * Correspondence: [email protected] Abstract: The SAM and HD domain-containing protein 1 (SAMHD1) is a dNTP triphosphohydrolase that plays a crucial role for a variety of different cellular functions. Besides balancing intracellular dNTP concentrations, facilitating DNA damage repair, and dampening excessive immune responses, SAMHD1 has been shown to act as a major restriction factor against various virus species. In addition to its well-described activity against retroviruses such as HIV-1, SAMHD1 has been identified to reduce the infectivity of different DNA viruses such as the herpesviruses CMV and EBV, the poxvirus VACV, or the hepadnavirus HBV. While some viruses are efficiently restricted by SAMHD1, others have developed evasion mechanisms that antagonize the antiviral activity of SAMHD1. Within this review, we summarize the different cellular functions of SAMHD1 and highlight the countermeasures viruses have evolved to neutralize the restriction factor SAMHD1. Keywords: SAMHD1; restriction factor; viral antagonism; HIV; herpesviruses; viral kinases; Vpx; dNTP hydrolase; viral interference 1. The dNTPase SAMHD1 The SAM and HD domain-containing protein 1 (SAMHD1) is a ubiquitously expressed Citation: Deutschmann, J.; deoxynucleotide triphosphohydrolase (dNTPase) of 626 amino acids (Figure1). In general, Gramberg, T. SAMHD1 . and Viral sterile alpha motif (SAM) domains have been shown to mediate protein–protein interaction Ways around It. Viruses 2021, 13, 395. or nucleic acid binding; however, its function in SAMHD1 is still unclear. The enzymatically https://doi.org/10.3390/v13030395 active HD domain, defined by two pairs of histidine and aspartate residues in its active center, on the other hand is essential for retroviral restriction and tetramerization of the Academic Editor: Sébastien Nisole protein [1–3].
    [Show full text]
  • DMD #9209 1 N-Methylpurine DNA Glycosylase and 8-Oxoguanine
    DMD Fast Forward. Published on March 24, 2006 as DOI: 10.1124/dmd.105.009209 DMD FastThis article Forward. has not beenPublished copyedited on and March formatted. 24, The 2006 final version as doi:10.1124/dmd.105.009209 may differ from this version. DMD #9209 N-methylpurine DNA glycosylase and 8-oxoguanine DNA glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole Philip L. Lorenzi1, Christopher P. Landowski2, Andrea Brancale, Xueqin Song, Leroy B. Townsend, John C. Drach and Gordon L. Amidon. Department of Pharmaceutical Sciences (P.L.L., C.P.L., X.S., G.L.A.) and Medicinal Chemistry (L.B.T., J.C.D.), College of Pharmacy, and Department of Biologic and Downloaded from Materials Sciences (J.C.D.), School of Dentistry, University of Michigan, Ann Arbor, Michigan, USA; and Welsh School of Pharmacy (A.B.), Cardiff University, Wales, UK. dmd.aspetjournals.org at ASPET Journals on September 24, 2021 1 Copyright 2006 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on March 24, 2006 as DOI: 10.1124/dmd.105.009209 This article has not been copyedited and formatted. The final version may differ from this version. DMD #9209 Running Title: Nucleoside drug metabolism by DNA repair enzymes Text pages: 19 Tables: 4 Figures: 3 References: 43 Words in Abstract: 180 Words in Introduction: 464 Words in Discussion: 1433 Abbreviations: BDCRB, 2-bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole; TCRB, 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole;
    [Show full text]
  • Novel Therapeutics for Epstein–Barr Virus
    molecules Review Novel Therapeutics for Epstein–Barr Virus Graciela Andrei *, Erika Trompet and Robert Snoeck Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] (E.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +32-16-321-915 Academic Editor: Stefano Aquaro Received: 15 February 2019; Accepted: 4 March 2019; Published: 12 March 2019 Abstract: Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.
    [Show full text]
  • Clinical Development of Letermovir and Maribavir Overview of Human
    Antiviral Research 163 (2019) 91–105 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Clinical development of letermovir and maribavir: Overview of human T cytomegalovirus drug resistance ∗ Jocelyne Piret, Guy Boivin Research Center in Infectious Diseases, CHU of Quebec and Laval University, Quebec City, QC, Canada ARTICLE INFO ABSTRACT Keywords: The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the use of antiviral Human cytomegalovirus agents that currently target the viral DNA polymerase and that may cause serious side effects. The search for Letermovir novel inhibitors against HCMV infection led to the discovery of new molecular targets, the viral terminase Maribavir complex and the viral pUL97 kinase. The most advanced compounds consist of letermovir (LMV) and maribavir Drug resistance (MBV). LMV inhibits the cleavage of viral DNA and its packaging into capsids by targeting the HCMV terminase Viral terminase complex complex. LMV is safe and well tolerated and exhibits pharmacokinetic properties that allow once daily dosing. Viral pUL97 kinase LMV showed efficacy in a phase III prophylaxis study in hematopoietic stem cell transplant (HSCT) recipients seropositive for HCMV. LMV was recently approved under the trade name Prevymis™ for prophylaxis of HCMV infection in adult seropositive recipients of an allogeneic HSCT. Amino acid substitutions conferring resistance to LMV selected in vitro map primarily to the pUL56 and rarely to the pUL89 and pUL51 subunits of the HCMV terminase complex. MBV is an inhibitor of the viral pUL97 kinase activity and interferes with the morphogenesis and nuclear egress of nascent viral particles. MBV is safe and well tolerated and has an excellent oral bioa- vailability.
    [Show full text]
  • Investigating Synergy Between Ribonucleotide Reductase Inhibitors and Cmv Antivirals
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 INVESTIGATING SYNERGY BETWEEN RIBONUCLEOTIDE REDUCTASE INHIBITORS AND CMV ANTIVIRALS Sukhada Bhave Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medicine and Health Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2838 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Sukhada Milind Bhave August 2012 All Rights Reserved INVESTIGATING SYNERGY BETWEEN RIBONUCLEOTIDE REDUCTASE INHIBITORS AND CMV ANTIVIRALS A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Sukhada Milind Bhave Bachelor of Pharmacy, Bombay College of Pharmacy, India, 2010 Major Director: Michael McVoy, Ph.D. Professor, Department of Microbiology and Immunology Virginia Commonwealth University Richmond, Virginia August 2012 ACKNOWLEDGEMENTS It is a pleasure to thank everyone who made this thesis possible. First, I would like to thank Dr. McVoy for accepting me as a graduate student in his lab and for his guidance and support through this project. I would also like to thank the other members of the McVoy lab: Frances Saccoccio, Anne Sauer, Xiao Cui, Ronzo Lee, Ben Wang, and Sabrina Prescott for sharing their expertise and helping me through various steps in the project. All of them indeed create a very cheerful and pleasant atmosphere in the lab.
    [Show full text]
  • Andrzej Szczeklik: Visionary, Pathfinder, Renaissance Man
    Andrzej Szczeklik: visionary, pathfinder, Renaissance man Jacek Hawiger Vanderbilt University School of Medicine, Nashville, Tennessee, United States Upon hearing the stunning news about Andrzej Szczeklik’s untimely death, I was overwhelmed by its suddenness. I learned from Andrzej’s wife, Maria, and daughter, Ania, how he was in the thick of things until his last days, planning the next Symposium, preparing his next book, and arranging the next trip. He was a patient in his beloved “Klinika”, the 2nd Department of Med- icine of the Jagiellonian University Medical Col- lege in Krakow. “Klinika” was his brainchild and work in progress ever since the communist au- thorities assigned Andrzej in 1972 to the Depart- ment of Allergy and Clinical Immunology while some of us, his peers, were getting junior faculty positions in Poland and abroad. Andrzej had cho- sen to stay in his native Poland and by espous- ing the philosophy of “Organic Work” had turned around his “Post”, the old dilapidated Tubercu- losis Hospital, into a modern marvel of Internal Medicine; he became its Chairman in 1989. By overcoming huge barriers, he transformed grim wards into functional patient rooms; a new wing was built with diagnostic and research labora- tories furnished with the state of the art equip- ment; a new lecture hall and conference rooms FIGURE 20 Professor Szczeklik in the Tatra Mountains were added, where Andrzej’s guests from Euro- that offered to him solace and inspiration; picture taken pean and American universities were sharing ad- by the author in 1992 vanced concepts and techno logical breakthroughs. A new cadre of students and fellows was rigorously trained to become highly accomplished physician- exploration of the vast range of genetic diversity -scientists and scientists.
    [Show full text]
  • The Third International Consensus Guidelinesthe on Management of Cytomegalovirus in Cincinnati, OH
    Original Clinical ScienceçGeneral The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation Camille N. Kotton, MD,1 Deepali Kumar, MD,2 Angela M. Caliendo, MD, PhD,3 Shirish Huprikar, MD,4 01/28/2019 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3pzrw1VmaZXQ+S1X5qzIxw8+AIlXMhR5CNF7trXzV+w4= by https://journals.lww.com/transplantjournal from Downloaded Sunwen Chou, MD,5 Lara Danziger-Isakov, MD, MPH,6 and Atul Humar, MD7 Downloaded on behalf of the The Transplantation Society International CMV Consensus Group from https://journals.lww.com/transplantjournal Abstract: Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized ap- proach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and expert opinion-based consensus guidelines on CMV management including prevention, treatment, diagnostics, immunology, drug resistance, and pediatric issues. Highlights include advances in molecular and immunologic diagnostics, improved understanding by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3pzrw1VmaZXQ+S1X5qzIxw8+AIlXMhR5CNF7trXzV+w4= of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immuno- suppressive agents, and more savvy approaches to treatment resistant/refractory disease. The following report summarizes the updated recommendations. (Transplantation 2018;102: 900–931) he past 5 years has seen exciting advances related to the convened in 2008 and 2012 by The Infectious Diseases Sec- Tunderstanding, diagnosis, and treatment of Cytomega- tion of The Transplantation Society to develop consensus lovirus (CMV).
    [Show full text]
  • Appendices: V Ervolgonderzoek Medicatieveiligheid
    APPENDICES: V ERVOLGONDERZOEK MEDICATIEVEILIGHEID Dit is een bijlage bij het rapport Vervolgonderzoek Medicatieveiligheid en is opgesteld voor het Ministerie van VWS vanuit een samenwerkingsverband tussen het Erasmus MC (Rotterdam), NIVEL (Utrecht), Radboud UMC (Nijmegen) en PHARMO (Utrecht) Januari 2017 Versie 1.0 1 Appendices Hoofstuk 2: Onderzoek naar de mate van opvolging van HARM-Wrestling aanbevelingen (2009-2014) 2 Appendix 1 Appendix 1: Technische omzetting van HARM-Wrestling aanbevelingen naar indicatoren Algemene specificaties Tabel A1a. Bepaling van medicatiegebruik. Geneesmiddel of ATC-code geneesmiddelen groep Antidepressiva N06A Laag gedoseerd ASA B01AC06, B01AC08, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Benzodiazepinen N05CF, N05CD, N05BA of N05CC Beta-blokkers C07 Bisfosfonaten M05BA, M05BB, of M05XX Calcineurine remmers L04AA05 of L04AD01 Carbamazepine N03AF01 Corticosteroiden H02AB Co-trimoxazol J01EE01 Coxibs M01AH Diabetesmedicatie A10 Digoxine C01AA05 Glibenclamide A10BB01 of A10BD02 of A10BD04 H2RA A02BA Itraconazol J02AC02 Kaliumsparende diuretica C03DA, C03DB, of C03EA Kaliumverliezende diuretica C03A, C03B, C03E, C07B, C07CB03, C09BA, C09DA, C09XA52, C03C of C09DX01 Ketoconazol J02AB02 Niet-selectieve NSAID’s N02BA01, N02BA15, N02BA11, N02BA51, N02BA65 of M01A met uitzondering van M01AH, M01AX05, M01AX12, M01AX21, M01AX24, M01AX25 en M01AX26 Laxantia A06A, A02AA02, A02AA03, A02AA04, A06AC, A06AA, of A06AG Lisdiuretica C03C Macroliden J01FA of A02BD04 VKA B01AA Opioïden N02AA met uitzondering van N02AA55, N02AA59 en N02AA79, N02AB, N02AC, N02AD, N02AG, N02AE of N07BC01 Pentamidine P01CX01 PPI’s A02BC of M01AE52 RAS-remmers C09 Sotalol C07AA07 Spironolacton C03DA01 SSRI's N06AB, N06AX21 of N06AX16 Sulonylureumderivaten A10BB, A10BD02 of A10BD04 Thiazidediuretica C03A, C03B, C03EA, C07B, C09BA, C09DA, C09XA52, C09DX01 of C07CB03 TAR B01AC04, B01AC06, B01AC08, B01AC22, B01AC30, N02BA15 (dosering 100mg) of N02BA01 (dosering 80mg) Thienopyridine derivaten B01AC04, B01AC22 of B01AC30 3 Appendix 1 Tabel A1b.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
    JULY 2019 MRx Pipeline A view into upcoming specialty and traditional drugs TABLE OF CONTENTS EDITORIAL STAFF Introduction Maryam Tabatabai, PharmD Editor in Chief Senior Director, Drug Information Pipeline Deep Dive Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Keep on Your Radar Consultant Panel Michelle Booth, Pharm D Director, Medical Pharmacy Strategy Becky Borgert, PharmD, BCOP Pipeline Drug List Director, Clinical Oncology Product Development Lara Frick, PharmD, BCPS, BCPP Drug Information Pharmacist Glossary Robert Greer, RPh, BCOP Senior Director, Clinical Strategy and Programs YuQian Liu, PharmD Manager, Specialty Clinical Programs Troy Phelps Senior Director, Analytics Nothing herein is or shall be construed as a promise or representation regarding past or future events and Magellan Rx Management expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Magellan Rx Management. 1 | magellanrx.com INTRODUCTION Welcome to the MRx Pipeline. In its third year of publication, this quarterly report offers clinical insights and competitive intelligence on anticipated drugs in development. Our universal forecast addresses trends applicable across market segments. Traditional and specialty drugs, agents under the pharmacy and medical benefits, new molecular entities, pertinent new and expanded indications for existing medications, and biosimilars are profiled in the report.
    [Show full text]
  • 7. Post-Transplant Infection Considerations
    7. Post-transplant infectious disease considerations Table of Contents 7.1 Viral 7.1.1 Cytomegalovirus 7.1.2 Epstein-Barr Virus and lymphoproliferative disorder 7.1.3 Herpes Simplex and Varicella-Zoster virus 7.1.4 Adenovirus infection 7.1.5 HBV prophylaxis and treatment 7.1.6 HCV prophylaxis and treatment 7.1.7 Arenavirus and West Nile Virus 7.1.8 BK Polyomavirus 7.1.9 Human Parvovirus 7.1.10 RNA Respiratory Viruses 7.2.11 Measles 7.2 Bacterial 7.2.1 Central venous catheter infections and treatment options 7.2.2 Mycobacterium tuberculosis 7.2.3 Non-tuberculosis mycobacterium 7.2.4 Nocardia 7.3 Fungal 7.3.1 PJP 7.3.2 Aspergillus 7.3.3 Cryptococcus 7.3.4 Invasive Candidiasis 7.3.5 Histoplasmosis 7.4 Other 7.4.1 Timing of post-transplant infections 7.4.2 Infectious exposure management 7.4.2.1 Measles 7.4.2.2 Varicella 7.4.2.3 Influenza 7.4.2.4 Tuberculosis 7.4.2.5 Bacterial Meningitis 7.4.3 Immunizations 7.4.4 Toxoplasmosis prophylaxis and treatment 7.1 Viral 7.1.1 Cytomegalovirus Singh N, et al (2020). Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients with Seropositive Donors. JAMA; 323(14):1378-1387. Retrieved from: https://jamanetwork.com/journals/jama/article-abstract/2764457 • Randomized clinical trial comparing the incidence of CMV disease in those high risk CMV liver transplant recipients who received preemptive therapy with valganciclovir 900mg twice daily to antiviral prophylaxis with valganciclovir 900mg daily.
    [Show full text]
  • Prof. Andrzej Szczeklik, 1938–2012: Aspirin-Induced Asthma and Much More
    Eur Respir J 2012; 39: 1283–1286 DOI: 10.1183/09031936.00054112 CopyrightßERS 2012 IN MEMORIAM Prof. Andrzej Szczeklik, 1938–2012: aspirin-induced asthma and much more We were sad to learn that Andrzej Szczeklik died on February 3, different occasions with rising doses of eight different analgesic 2012 after a short period of cardiac illness. We seek comfort in drugs. Indomethacin, mefenamic acid, flufenamic acid and his many achievements that remain and which will continue to phenylbutazone triggered bronchoconstriction in therapeutic or inspire and guide future generations of scientists and clinicians. lower doses, whereas even high doses of salicylamide, para- cetamol, benzydamine and chloroquine were tolerated. The Among respiratory physicians and allergologists, Szczeklik will ability of the drugs to elicit adverse reactions correlated directly certainly be remembered as the world-leading authority on with their effectiveness to inhibit prostaglandin biosynthesis in aspirin-induced asthma. At this juncture it is somewhat ironic vitro. These results unequivocally demonstrated that the intoler- that he, outside our field, is known because of a number of key ance reaction was related to inhibition of prostaglandin biosynth- basic and clinical findings relating to diagnosis and treatment of esis. Sadly enough, even today there are occasional deaths due to thrombosis and cardiovascular disease. In fact, the Polish Nobel failure among health professionals to recognise that the intoler- Laureate in Literature, Czeslaw Milosz, who wrote the foreword ance is a class effect of all nonsteroidal anti-inflammatory drugs to Szczeklik’s book Catharsis [1], described Szczeklik as a world (NSAIDs) that inhibit the cyclo-oxygenase (COX) reaction.
    [Show full text]